Amalgamated Bank’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-8,675
| Closed | -$16K | – | 2475 |
|
|
2025
Q4 | $16K | Sell |
8,675
-766
| -8% | -$1.47K | ﹤0.01% | 2218 |
|
|
2025
Q3 | $12K | Hold |
9,441
| – | – | ﹤0.01% | 2387 |
|
|
2025
Q2 | $12K | Hold |
9,441
| – | – | ﹤0.01% | 2370 |
|
|
2025
Q1 | $11K | Buy |
9,441
+1,213
| +15% | +$1.86K | ﹤0.01% | 2334 |
|
|
2024
Q4 | $15K | Hold |
8,228
| – | – | ﹤0.01% | 2250 |
|
|
2024
Q3 | $14K | Hold |
8,228
| – | – | ﹤0.01% | 2294 |
|
|
2024
Q2 | $11K | Hold |
8,228
| – | – | ﹤0.01% | 2399 |
|
|
2024
Q1 | $31K | Sell |
8,228
-20,996
| -72% | -$123K | ﹤0.01% | 1997 |
|
|
2023
Q4 | $287K | Sell |
29,224
-2,449
| -8% | -$20K | ﹤0.01% | 1671 |
|
|
2023
Q3 | $264K | Hold |
31,673
| – | – | ﹤0.01% | 1684 |
|
|
2023
Q2 | $421K | Buy |
31,673
+6,522
| +26% | +$79.3K | ﹤0.01% | 1519 |
|
|
2023
Q1 | $291K | Sell |
25,151
-4,794
| -16% | -$47.7K | ﹤0.01% | 1654 |
|
|
2022
Q4 | $245K | Buy |
29,945
+1,057
| +4% | +$9.11K | ﹤0.01% | 1780 |
|
|
2022
Q3 | $168K | Buy |
28,888
+281
| +1% | +$1.61K | ﹤0.01% | 1914 |
|
|
2022
Q2 | $126K | Buy |
28,607
+1,374
| +5% | +$8.35K | ﹤0.01% | 2080 |
|
|
2022
Q1 | $248K | Sell |
27,233
-2,096
| -7% | -$24.1K | ﹤0.01% | 1854 |
|
|
2021
Q4 | $600K | Sell |
29,329
-291
| -1% | -$7.02K | ﹤0.01% | 1495 |
|
|
2021
Q3 | $757K | Sell |
29,620
-1,995
| -6% | -$59.1K | 0.01% | 1387 |
|
|
2021
Q2 | $1.11M | Buy |
31,615
+7,047
| +29% | +$205K | 0.01% | 1240 |
|
|
2021
Q1 | $818K | Sell |
24,568
-1,470
| -6% | -$51.5K | 0.03% | 695 |
|
|
2020
Q4 | $675K | Buy |
26,038
+1,714
| +7% | +$29.1K | 0.03% | 787 |
|
|
2020
Q3 | $240K | Buy |
24,324
+2,482
| +11% | +$14.3K | 0.01% | 1231 |
|
|
2020
Q2 | $75K | Sell |
21,842
-3,385
| -13% | -$11.5K | ﹤0.01% | 1429 |
|
|
2020
Q1 | $77K | Sell |
25,227
-543
| -2% | -$2.22K | ﹤0.01% | 1525 |
|
|
2019
Q4 | $132K | Buy |
25,770
+807
| +3% | +$4.1K | ﹤0.01% | 1702 |
|
|
2019
Q3 | $129K | Sell |
24,963
-155
| -0.6% | -$867 | ﹤0.01% | 1623 |
|
|
2019
Q2 | $152K | Buy |
25,118
+4,543
| +22% | +$31.9K | ﹤0.01% | 1637 |
|
|
2019
Q1 | $149K | Buy |
20,575
+717
| +4% | +$5.19K | ﹤0.01% | 1559 |
|
|
2018
Q4 | $147K | Buy |
+19,858
| New | +$126K | ﹤0.01% | 1467 |
|
|
2018
Q3 | – | Sell |
-18,738
| Closed | -$67K | – | 1568 |
|
|
2018
Q2 | $67K | Buy |
18,738
+3,020
| +19% | +$8.38K | ﹤0.01% | 1680 |
|
|
2018
Q1 | $32K | Buy |
15,718
+1,565
| +11% | +$4.06K | ﹤0.01% | 1592 |
|
|
2017
Q4 | $37K | Buy |
14,153
+1,029
| +8% | +$3.6K | ﹤0.01% | 1632 |
|
|
2017
Q3 | $69K | Buy |
13,124
+2,367
| +22% | +$10.2K | ﹤0.01% | 1531 |
|
|
2017
Q2 | $38K | Buy |
+10,757
| New | +$43.4K | ﹤0.01% | 1555 |
|
Other funds holding PACB
AIM
VCM
NAMA
Amalgamated Bank's PACB Position: Q1 2026 in Review
Amalgamated Bank sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 8,675 shares — an estimated $16K sold.
Amalgamated Bank first reported a position in PACB in Q2 2017 and held it in 34 quarters. The position peaked at $1.11M in Q2 2021. 230 funds tracked by Wall St. Rank hold PACB as of Q1 2026.
- Amalgamated Bank reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
- Amalgamated Bank sold 8,675 Pacific Biosciences shares in Q1 2026, an estimated $16K.
- Amalgamated Bank first reported a position in Pacific Biosciences in Q2 2017 and held it in 34 quarters.
- Amalgamated Bank's Pacific Biosciences position peaked at $1.11M in Q2 2021.
- 230 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.
Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.